$BNET
BION ENVIRONMENTAL TECHNOLOGIES INC

2021 Q1 Form 10-Q Financial Statement

#000107997321000361 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1 2019
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.114M $268.8K $1.725M
YoY Change 314.59% -11.92% -26.15%
% of Gross Profit
Research & Development $332.2K $135.1K $237.8K
YoY Change 145.98% 30.45% -79.94%
% of Gross Profit
Depreciation & Amortization $206.00 $347.00 $694.00
YoY Change -40.63% 28.04% -60.21%
% of Gross Profit
Operating Expenses $1.447M $404.2K $946.2K
YoY Change 257.94% -1.16% -73.14%
Operating Profit -$1.447M -$404.2K -$946.2K
YoY Change 257.94% -1.16% -73.14%
Interest Expense $137.9K $103.1K $260.3K
YoY Change 33.79% 2.79% -27.78%
% of Operating Profit
Other Income/Expense, Net -$103.1K -$103.1K -$260.3K
YoY Change 0.03% 2.79% -151.6%
Pretax Income -$1.550M -$507.3K -$2.659M
YoY Change 205.53% -0.38% -11.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.550M -$507.3K -$2.659M
YoY Change 205.53% -0.38% -11.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$47.04K -$17.10K -$100.1K
COMMON SHARES
Basic Shares Outstanding 29.54M
Diluted Shares Outstanding 32.92M 29.64M 26.52M

Balance Sheet

Concept 2021 Q1 2020 Q1 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.671M $356.6K $41.34K
YoY Change 368.49% 139.07% 87.82%
Cash & Equivalents $1.671M $356.6K
Short-Term Investments
Other Short-Term Assets $7.060K $4.980K $9.010K
YoY Change 41.77% -3.49% 6.38%
Inventory
Prepaid Expenses $6.059K $3.983K
Receivables
Other Receivables $1.000K
Total Short-Term Assets $1.678M $361.6K $50.34K
YoY Change 363.98% 134.3% 65.1%
LONG-TERM ASSETS
Property, Plant & Equipment $748.00 $1.575K $2.620K
YoY Change -52.51% -46.86% 80.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $748.00 $1.575K $2.620K
YoY Change -52.51% -46.86% 80.69%
TOTAL ASSETS
Total Short-Term Assets $1.678M $361.6K $50.34K
Total Long-Term Assets $748.00 $1.575K $2.620K
Total Assets $1.679M $363.2K $52.96K
YoY Change 362.18% 130.89% 65.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $548.9K $719.9K $715.6K
YoY Change -23.75% 7.05% -0.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.798M $9.506M $9.303M
YoY Change 3.07% 3.01% 3.04%
Total Short-Term Liabilities $11.40M $10.91M $10.93M
YoY Change 4.42% 1.26% 7.1%
LONG-TERM LIABILITIES
Long-Term Debt $4.748M $4.560M $3.801M
YoY Change 4.13% 25.98% 7.83%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.748M $4.560M $3.801M
YoY Change 4.13% 25.98% 7.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.40M $10.91M $10.93M
Total Long-Term Liabilities $4.748M $4.560M $3.801M
Total Liabilities $16.14M $15.47M $14.78M
YoY Change 4.33% 7.47% 7.23%
SHAREHOLDERS EQUITY
Retained Earnings -$131.7M -$126.1M
YoY Change 4.47% 1.96%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.50M -$15.16M -$14.72M
YoY Change
Total Liabilities & Shareholders Equity $1.679M $363.2K $52.96K
YoY Change 362.18% 130.89% 65.81%

Cashflow Statement

Concept 2021 Q1 2020 Q1 2019
OPERATING ACTIVITIES
Net Income -$1.550M -$507.3K -$2.659M
YoY Change 205.53% -0.38% -11.9%
Depreciation, Depletion And Amortization $206.00 $347.00 $694.00
YoY Change -40.63% 28.04% -60.21%
Cash From Operating Activities -$355.2K -$276.4K -$811.1K
YoY Change 28.54% 39.83% 73.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.482K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.482K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.665M 163.8K 832.9K
YoY Change 916.33% -46.47% 100.0%
NET CHANGE
Cash From Operating Activities -355.2K -276.4K -811.1K
Cash From Investing Activities 0.000 -2.482K
Cash From Financing Activities 1.665M 163.8K 832.9K
Net Change In Cash 1.310M -112.6K 19.32K
YoY Change -1263.51% -206.29% -137.95%
FREE CASH FLOW
Cash From Operating Activities -$355.2K -$276.4K -$811.1K
Capital Expenditures $0.00 $2.482K
Free Cash Flow -$276.4K -$813.6K
YoY Change 41.61% 74.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
36239
bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
212645
bnet Adjustment To Additional Paid In Capital Modification Ofoptions
AdjustmentToAdditionalPaidInCapitalModificationOfoptions
8775
bnet Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5000
bnet Common Stock Shares Issued Upon Exercise Of Warrants
CommonStockSharesIssuedUponExerciseOfWarrants
5000
bnet Common Stock Voting Rights Votes Per Share
CommonStockVotingRightsVotesPerShare
1
CY2021Q1 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
CY2020Q2 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
168151
bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
71658
bnet Conversion Of Deferred Compensation Into Note Payable Affiliate
ConversionOfDeferredCompensationIntoNotePayableAffiliate
bnet Conversion Of Deferred Compensation Into Note Payable Affiliate
ConversionOfDeferredCompensationIntoNotePayableAffiliate
636081
bnet Deferred Compensation Consecutive Trading Days
DeferredCompensationConsecutiveTradingDays
P10D
bnet Deferred Compensation Conversion Days
DeferredCompensationConversionDays
P5D
CY2018 bnet Deferred Compensation Liability Amount Cancelled
DeferredCompensationLiabilityAmountCancelled
2404000
CY2013Q2 bnet Extension Of Exercise Period Annual Payment Per Option Or Warrant
ExtensionOfExercisePeriodAnnualPaymentPerOptionOrWarrant
0.05
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
628926
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794877
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794257
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
117688204
CY2020Q4 bnet Interest Rate On Deferred Compensation
InterestRateOnDeferredCompensation
0.04
CY2021Q1 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9797842
CY2020Q2 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9585883
bnet Loans Payable To Affiliates
LoansPayableToAffiliates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">LOANS PAYABLE:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;">Pennvest</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">PA1,</div> the Company's wholly-owned subsidiary, owes <div style="display: inline; font-style: italic; font: inherit;">$9,797,842</div> as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021 </div>under the terms of the Pennvest Loan related to the construction of the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System including accrued interest and late charges totaling <div style="display: inline; font-style: italic; font: inherit;">$2,043,842</div> as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021. </div>The terms of the Pennvest Loan provided for funding of up to <div style="display: inline; font-style: italic; font: inherit;">$7,754,000</div> which was to be repaid by interest-only payments for <div style="display: inline; font-style: italic; font: inherit;">three</div> years, followed by an additional <div style="display: inline; font-style: italic; font: inherit;">ten</div>-year amortization of principal. The Pennvest Loan accrues interest at <div style="display: inline; font-style: italic; font: inherit;">2.547%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">1</div> through <div style="display: inline; font-style: italic; font: inherit;">5</div> and <div style="display: inline; font-style: italic; font: inherit;">3.184%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">6</div> through maturity. The Pennvest Loan required minimum annual principal payments of approximately <div style="display: inline; font-style: italic; font: inherit;">$5,067,000</div> in fiscal years <div style="display: inline; font-style: italic; font: inherit;">2013</div> through <div style="display: inline; font-style: italic; font: inherit;">2020,</div> and <div style="display: inline; font-style: italic; font: inherit;">$819,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2021,</div> <div style="display: inline; font-style: italic; font: inherit;">$846,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2022,</div> <div style="display: inline; font-style: italic; font: inherit;">$873,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2023</div> and <div style="display: inline; font-style: italic; font: inherit;">$149,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2024.</div> The Pennvest Loan is collateralized by the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System and by a pledge of all revenues generated from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$61,722</div></div> for both the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021 </div>and <div style="display: inline; font-style: italic; font: inherit;">2020,</div> respectively. The Company has also incurred interest expense related to the Pennvest Loan of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$185,166</div></div> for both the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021 </div>and <div style="display: inline; font-style: italic; font: inherit;">2020,</div> respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> has elected <div style="display: inline; font-style: italic; font: inherit;">not</div> to make interest payments to Pennvest on the Pennvest Loan since <div style="display: inline; font-style: italic; font: inherit;"> January 2013. </div>Additionally, the Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> made any principal payments, which were to begin in fiscal <div style="display: inline; font-style: italic; font: inherit;">2013,</div> and, therefore, the Company has classified the Pennvest Loan as a current liability as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <div style="display: inline; font-style: italic; font: inherit;"> September 25, 2014, </div>Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that <div style="display: inline; font-style: italic; font: inherit;">PA1</div> pay <div style="display: inline; font-style: italic; font: inherit;">$8,137,117</div> (principal, interest plus late charges) on or before <div style="display: inline; font-style: italic; font: inherit;"> October 24, 2014. </div><div style="display: inline; font-style: italic; font: inherit;">PA1</div> did <div style="display: inline; font-style: italic; font: inherit;">not</div> make the payment and does <div style="display: inline; font-style: italic; font: inherit;">not</div> have the resources to make the payments demanded by Pennvest. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected <div style="display: inline; font-style: italic; font: inherit;">PA1's</div> proposal made during the fall of <div style="display: inline; font-style: italic; font: inherit;">2014.</div> <div style="display: inline; font-style: italic; font: inherit;">No</div> formal proposals are presently under consideration and only sporadic communication has taken place regarding the matters involved over the last <div style="display: inline; font-style: italic; font: inherit;">7</div> years. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> provides Pennvest with its financial statements (which include a description of system status) annually. During the current fiscal year, Pennvest's auditors requested a &#x2018;corrective action plan' and <div style="display: inline; font-style: italic; font: inherit;">PA1</div> informed Pennvest that &#x201c;&#x2026; there is <div style="display: inline; font-style: italic; font: inherit;">no</div> viable corrective action plan for the Pennvest Loan (&#x2018;Loan'). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA <div style="display: inline; font-style: italic; font: inherit;">1,</div> LLC) and the technology utilized in the facility is now obsolete. The facility has <div style="display: inline; font-style: italic; font: inherit;">not</div> been commercially operated for approximately <div style="display: inline; font-style: italic; font: inherit;">six</div> years and has generated <div style="display: inline; font-style: italic; font: inherit;">zero</div> income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.&#x201d; &nbsp;Pennvest recently responded&nbsp; favorably to the &nbsp;approach of selling the equipment but <div style="display: inline; font-style: italic; font: inherit;">no</div> actions have yet taken place. The Company expects to have additional communication with Pennvest on this matter during the current quarter. It is <div style="display: inline; font-style: italic; font: inherit;">not</div> possible at this date to predict the final outcome of this matter, but the Company believes it is likely that that the equipment will be sold with the proceeds delivered to Pennvest during our next fiscal year. However, the manner and means of such equipment sale has <div style="display: inline; font-style: italic; font: inherit;">not</div> been agreed upon as of this date. It remains possible that a loan modification agreement (coupled with an agreement regarding a technology update and re-start of full operations at the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> dairy) <div style="display: inline; font-style: italic; font: inherit;"> may </div>be reached in the future in the context of the development of the Kreider <div style="display: inline; font-style: italic; font: inherit;">2</div> poultry Project if/when a more robust market for nutrient reductions develops in Pennsylvania, of which there is <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> will evaluate the appropriate manner to resolve/wrap-up its business over the balance of this calendar year.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Pennvest Loan financing documents, the Company provided a &#x2018;technology guaranty' regarding nutrient reduction performance of Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> which was structured to expire when Kreider <div style="display: inline; font-style: italic; font: inherit;">1's</div> nutrient reduction performance had been demonstrated. During <div style="display: inline; font-style: italic; font: inherit;"> August 2012 </div>the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System had surpassed the requisite performance criteria and that the Company's &#x2018;technology guaranty' was met. As a result, the Pennvest Loan is solely an obligation of <div style="display: inline; font-style: italic; font: inherit;">PA1.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><div style="display: inline; font-weight: bold;">Paycheck Protection Program</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>the Company received proceeds from a loan in the amount of <div style="display: inline; font-style: italic; font: inherit;">$34,800</div> from Covenant Bank as the lender, pursuant to the Small Business Administration (&#x201c;SBA&#x201d;) Paycheck Protection Program (&#x201c;PPP&#x201d;) under the Coronavirus Aid, Relief, and Economic Security (&#x201c;CARES&#x201d;) Act. The loan was uncollateralized, had a fixed interest rate of <div style="display: inline; font-style: italic; font: inherit;">one</div> percent, a term of <div style="display: inline; font-style: italic; font: inherit;">two</div> years and the <div style="display: inline; font-style: italic; font: inherit;">first</div> payment is deferred for <div style="display: inline; font-style: italic; font: inherit;">six</div> months. Under the CARES Act, borrowers were eligible for forgiveness of principal and interest on PPP loans to the extent that the proceeds were used to cover eligible payroll costs, rent and utility costs over either an <div style="display: inline; font-style: italic; font: inherit;">8</div>- or <div style="display: inline; font-style: italic; font: inherit;">24</div>-week period after the loan was made. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>the total PPP loan and accrued interest was fully forgiven by the SBA.</div></div>
bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
1850000
bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
1159000
bnet Sale Of Units Value
SaleOfUnitsValue
1159000
bnet Sale Of Units Value
SaleOfUnitsValue
1850000
CY2021Q1 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
CY2020Q1 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
105400
bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
160000
bnet Warrants Exercised For Common Stock
WarrantsExercisedForCommonStock
3750
bnet Warrants Issued For Unit Commissions
WarrantsIssuedForUnitCommissions
16100
bnet Warrants Issued For Unit Commissions
WarrantsIssuedForUnitCommissions
10984
bnet Weighted Average Exercise Price For Outstanding Warrants
WeightedAverageExercisePriceForOutstandingWarrants
0.73
CY2021Q1 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
1353526
CY2020Q1 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
150242
bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
919613
bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
1269223
bnet Weighted Average Remaining Contractual Life For Outstanding Warrants
WeightedAverageRemainingContractualLifeForOutstandingWarrants
P2Y292D
CY2021Q1 bnet Working Capital
WorkingCapital
9718000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
548914
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114266683
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
99500
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1017700
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1250
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2500
CY2021Q1 us-gaap Assets
Assets
1678527
CY2020Q2 us-gaap Assets
Assets
571161
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1677779
CY2020Q2 us-gaap Assets Current
AssetsCurrent
569793
CY2021Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2020Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2021Q1 us-gaap Cash
Cash
1670720
CY2020Q2 us-gaap Cash
Cash
560828
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
560828
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41335
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1670720
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
356619
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1109892
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
315284
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
24700000
CY2021Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2020Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35786310
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31409005
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32270594
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30195005
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28068688
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35082001
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30704696
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31566285
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29490696
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27364379
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><div style="display: inline; font-weight: bold;">Concentrations of credit risk:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times <div style="display: inline; font-style: italic; font: inherit;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on such accounts.</div></div></div></div></div></div></div></div></div></div></div>
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
34800
CY2009Q1 us-gaap Construction Loan
ConstructionLoan
7750000
CY2021Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4747829
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4595841
CY2021Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1012159
CY2020Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
652367
CY2020Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
778217
CY2021Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2020Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2021Q1 us-gaap Depreciation
Depreciation
206
CY2020Q1 us-gaap Depreciation
Depreciation
347
us-gaap Depreciation
Depreciation
620
us-gaap Depreciation
Depreciation
1041
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
34800
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1114298
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
268771
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1708857
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
976525
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-39521
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
57195
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
341705
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
399616
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1906
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4022
CY2021Q1 us-gaap Interest Expense
InterestExpense
137911
CY2020Q1 us-gaap Interest Expense
InterestExpense
103084
us-gaap Interest Expense
InterestExpense
545422
us-gaap Interest Expense
InterestExpense
363424
us-gaap Interest Paid Net
InterestPaidNet
28
us-gaap Interest Paid Net
InterestPaidNet
CY2021Q1 us-gaap Liabilities
Liabilities
16143644
CY2020Q2 us-gaap Liabilities
Liabilities
15659119
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1678527
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
571161
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11395815
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11043359
CY2021Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2020Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2021Q1 us-gaap Minority Interest
MinorityInterest
39644
CY2020Q2 us-gaap Minority Interest
MinorityInterest
41902
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1993750
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1068600
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-883858
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-753316
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1219
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-516
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2258
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1789
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1548604
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-506743
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2796422
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1712037
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-103111
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-103084
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-510622
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-363424
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1446712
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
404175
us-gaap Operating Expenses
OperatingExpenses
2288058
us-gaap Operating Expenses
OperatingExpenses
1350402
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1446712
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-404175
us-gaap Operating Income Loss
OperatingIncomeLoss
-2288058
us-gaap Operating Income Loss
OperatingIncomeLoss
-1350402
us-gaap Other Noncash Expense
OtherNoncashExpense
572431
us-gaap Other Noncash Expense
OtherNoncashExpense
381536
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
160000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
105400
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6059
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7965
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
300000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1584000
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
897000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2150000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
35000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3750
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2020 us-gaap Profit Loss
ProfitLoss
-4553000
CY2019 us-gaap Profit Loss
ProfitLoss
-2659000
us-gaap Profit Loss
ProfitLoss
-2798680
us-gaap Profit Loss
ProfitLoss
-1713826
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-1549823
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-507259
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
748
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1368
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
20000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
332208
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135057
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
578581
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372836
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131688315
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128891893
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap Share Based Compensation
ShareBasedCompensation
1072481
us-gaap Share Based Compensation
ShareBasedCompensation
117100
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10471600
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
960000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.06
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10252975
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9511600
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10471600
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.10
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10252975
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y328D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y182D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y328D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1017700
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
99500
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
960000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.06
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
36900
CY2020Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
35400
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
71658
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
168151
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16350
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
18000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-14504761
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-15129860
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14465117
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15087958
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14674598
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15109827
CY2021Q1 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
CY2020Q2 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
14933
CY2021Q1 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
CY2020Q2 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
19919
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><div style="display: inline; font-weight: bold;">Use of estimates:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In preparing the Company's consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div>
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32919811
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29640938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31624309
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28633602
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32919811
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29640938
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31624309
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28633602

Files In Submission

Name View Source Status
0001079973-21-000361-index-headers.html Edgar Link pending
0001079973-21-000361-index.html Edgar Link pending
0001079973-21-000361.txt Edgar Link pending
0001079973-21-000361-xbrl.zip Edgar Link pending
bion_10q-033121.htm Edgar Link pending
bnet-20210331.xml Edgar Link completed
bnet-20210331.xsd Edgar Link pending
bnet-20210331_cal.xml Edgar Link unprocessable
bnet-20210331_def.xml Edgar Link unprocessable
bnet-20210331_lab.xml Edgar Link unprocessable
bnet-20210331_pre.xml Edgar Link unprocessable
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending